-1753361183599.webp&w=3840&q=75)
2025 NOSCM | Where Are We in Treating Lung Cancer Driven by KRAS and HER2?
Overview
Dr. Erminia Massarelli discussed second-generation KRAS inhibitors that show higher potency and lower toxicity compared to first-generation inhibitors. The combination of KRAS inhibitors and immunotherapy is being studied, with promising results in first-line settings.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Erminia Massarelli, MD, PhD, MS
Date of Release
July 24th, 2025
-1755990775594.webp&w=3840&q=75)
-1755990700517.webp&w=3840&q=75)